

Interim Financial Statements (Un-audited)
For the period July - December 2020



Beximco Pharmaceuticals Limited

**Financial Statements (Un-audited)
Consolidated**

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Financial Position (Un-audited)
As at December 31, 2020

	Notes	December 31, 2020	Taka '000 June 30, 2020
ASSETS			
Non-Current Assets			
Property, Plant and Equipment- Carrying Value	4	37,372,535	37,069,663
Right-of-use Assets		35,341,190	35,000,810
Intangible Assets		234,574	240,164
Goodwill		1,238,826	1,275,561
Other Investment	5	546,691	546,691
Other Non-current Assets		11,254	3,751
		-	2,686
Current Assets			
Inventories	6	13,816,614	13,049,079
Spares & Supplies		6,769,702	5,944,769
Accounts Receivable		858,381	775,529
Loans, Advances and Deposits	7	2,909,203	3,305,451
Cash and Cash Equivalents	8	2,884,723	2,388,313
		394,605	635,017
TOTAL ASSETS		51,189,149	50,118,742
SHAREHOLDERS' EQUITY AND LIABILITIES			
Equity Attributable to the Owners of the Company			
Issued Share Capital		34,103,871	32,495,121
Share Premium		4,461,120	4,055,564
Excess of Issue Price over Face Value of GDRs		5,269,475	5,269,475
Capital Reserve on Merger		1,689,637	1,689,637
Revaluation Surplus		294,951	294,951
Unrealized Gain/(Loss)		1,123,076	1,125,768
Retained Earnings		8,429	926
		21,257,183	20,058,800
Non-Controlling Interest		313,866	302,329
TOTAL EQUITY		34,417,737	32,797,450
Non-Current Liabilities			
Long Term Borrowings-Net of Current Maturity	9 A	5,951,596	5,963,327
Liability for Gratuity and WPPF & Welfare Funds		1,408,265	1,651,590
Deferred Tax Liability		2,348,485	2,144,053
		2,194,846	2,167,684
Current Liabilities and Provisions			
Short Term Borrowings		10,819,816	11,357,965
Long Term Borrowings-Current Maturity	9 B	6,359,665	7,398,361
Creditors and Other Payables		1,169,234	1,454,312
Accrued Expenses		1,198,349	1,397,817
Dividend Payable / Unclaimed Dividend	10	847,009	739,513
Income Tax Payable		689,788	82,075
		555,771	285,887
TOTAL EQUITY AND LIABILITIES		51,189,149	50,118,742

Osman Kaiser Chowdhury
Director

A B Siddiqur Rahman
Director

Nazmul Hassan
Managing Director

Mohammad Ali Nawaz
Chief Financial Officer

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July-December 2020

	Notes	July - December 2020	July - December 2019	October - December 2020	October - December 2019
					Taka '000
Net Revenue		14,400,189	12,495,526	7,474,259	6,192,191
Cost of Goods Sold	11	(7,568,599)	(6,687,655)	(3,932,210)	(3,325,974)
Gross Profit		6,831,590	5,807,871	3,542,049	2,866,217
Operating Expenses		(3,364,722)	(3,049,977)	(1,744,949)	(1,541,859)
Administrative Expenses	12	(403,632)	(388,704)	(206,306)	(200,227)
Selling, Marketing and Distribution Expenses	13	(2,961,090)	(2,661,273)	(1,538,643)	(1,341,632)
Profit from Operations		3,466,868	2,757,894	1,797,100	1,324,358
Other Income	14	169,913	136,765	75,817	76,645
Finance Cost		(502,855)	(532,325)	(269,459)	(228,287)
Profit Before Contribution to WPPF & Welfare Funds		3,133,926	2,362,334	1,603,458	1,172,716
Contribution to WPPF & Welfare Funds		(151,915)	(114,467)	(78,529)	(57,316)
Profit Before Tax		2,982,011	2,247,867	1,524,929	1,115,400
Income Tax Expenses		(755,712)	(532,521)	(382,971)	(269,929)
Current Tax		(727,652)	(528,146)	(368,973)	(257,488)
Deferred Tax	15	(28,060)	(4,375)	(13,998)	(12,441)
Profit After Tax		2,226,299	1,715,346	1,141,958	845,471
Profit/(Loss) Attributable to:					
Owners of the Company		2,208,684	1,706,419	1,134,206	841,659
Non-controlling interest		17,615	8,927	7,752	3,812
		2,226,299	1,715,346	1,141,958	845,471
Other Comprehensive Income-Unrealized Gain/(Loss)		7,503	(1,444)	5,606	(773)
Total Comprehensive Income		2,233,802	1,713,902	1,147,564	844,698
Total Comprehensive Income Attributable to:					
Owners of the Company		2,216,187	1,704,975	1,139,812	840,886
Non-controlling interest		17,615	8,927	7,752	3,812
		2,233,802	1,713,902	1,147,564	844,698
Earnings Per Share (EPS)/Restated EPS	16	4.95	3.83	2.54	1.89
Number of Shares Used to Compute EPS	Nos.	446,112,089	446,112,089	446,112,089	446,112,089

Osman Kaiser Chowdhury
Director

A B Siddiquir Rahman
Director

Nazmul Hassan
Managing Director

Mohammad Ali Nawaz
Chief Financial Officer

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Changes in Equity (Un-audited)
For the Period July-December 2020

As at December 31, 2020

Taka' 000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to the Owners of the Company	Non-Controlling Interests	Total Equity	
Balance as on July 01, 2020	4,055,564	5,269,475	1,689,637	294,951	1,125,768	926	20,058,800	32,495,121	302,329	32,797,450	
Total Comprehensive Income:											
Profit/(Loss) for the Period	-	-	-	-	-	-	2,208,684	2,208,684	17,615	2,226,299	
Other Comprehensive Income/(Loss)	-	-	-	-	-	7,503	-	7,503	-	7,503	
Transactions with the Shareholders:											
Cash Dividend	-	-	-	-	-	-	(608,335)	(608,335)	(6,078)	(614,413)	
Stock Dividend	405,556	-	-	-	-	-	(405,556)	-	-	-	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(3,590)	-	3,590	-	-	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	898	-	-	898	-	898	
Balance as on December 31, 2020	4,461,120	5,269,475	1,689,637	294,951	1,123,076	8,429	21,257,183	34,103,871	313,866	34,417,737	
Number of Shares										446,112,089	
Net Asset Value (NAV) Per Share								Tk.	76.45		

As at December 31, 2019

Taka' 000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to the Owners of the Company	Non-Controlling Interests	Total Equity	
Balance as on July 01, 2019	4,055,564	5,269,475	1,689,637	294,951	1,131,853	2,504	17,144,333	29,588,317	276,007	29,864,324	
Total Comprehensive Income:											
Profit/(Loss) for the Period	-	-	-	-	-	-	1,706,419	1,706,419	8,927	1,715,346	
Other Comprehensive Income/(Loss)	-	-	-	-	-	(1,444)	-	(1,444)	-	(1,444)	
Transactions with the Shareholders:											
Cash Dividend	-	-	-	-	-	-	(608,335)	(608,335)	(3,473)	(611,808)	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(4,057)	-	4,057	-	-	-	
Balance as on December 31, 2019	4,055,564	5,269,475	1,689,637	294,951	1,127,796	1,060	18,246,474	30,684,957	281,461	30,966,418	
Number of Shares										405,556,445	
Net Asset Value (NAV) Per Share									75.66		

Osman Kaiser Chowdhury
Director

A B Siddiqur Rahman
Director

Nazmul Hassan
Managing Director

Mohammad Ali Nawaz
Chief Financial Officer

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Cash Flows (Un-audited)
For the Period July-December 2020

	Notes	July - December 2020	Taka '000 July - December 2019
Cash Flows from Operating Activities :			
Receipts from Customers and Others		14,968,135	12,970,054
Payments to Suppliers and Employees		(11,819,166)	(8,533,250)
Cash Generated from Operations		3,148,969	4,436,804
Interest Paid		(502,855)	(532,325)
Interest Received		1,318	15,547
Income Tax Paid		(457,768)	(212,520)
Net Cash Generated from Operating Activities	17	2,189,664	3,707,506
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(864,972)	(1,309,616)
Intangible Assets		(8,819)	(13,065)
Disposal of Property, Plant and Equipment		21,171	3,342
Decrease in Short Term Investment		-	127,785
Net Cash Used in Investing Activities		(852,620)	(1,191,554)
Cash Flows from Financing Activities :			
Net Increase /(Decrease) in Long Term Borrowings		(532,178)	(750,702)
Net Increase/(Decrease) in Short Term Borrowings		(1,038,577)	(1,875,555)
Dividend Paid		(6,701)	(3,862)
Net Cash (Used in) / from Financing Activities		(1,577,456)	(2,630,119)
Increase/(Decrease) in Cash and Cash Equivalents		(240,412)	(114,167)
Cash and Cash Equivalents at Beginning of Period		635,017	610,494
Effect of exchange rate changes on Cash and Cash Equivalents*		-	606
Cash and Cash Equivalents at End of Period	8	394,605	496,933
Net Operating Cash Flow Per Share		4.91	9.14

*The Company used Janata Bank's end of periods US Dollar-BDT exchange rates as on 31 December 2020 which remained unchanged with the exchange rates as at 30 June 2020. As such there was no effect of exchange rates in the cash flow.

 Osman Kaiser Chowdhury Director	 A B Siddiqui Rahman Director	 Nazmul Hassan Managing Director	 Mohammad Ali Nawaz Chief Financial Officer	 Mohammad Asad Ullah, FCS Executive Director & Company Secretary
--	---	--	--	--

Beximco Pharmaceuticals Limited and its Subsidiaries
Selected Notes to the Financial Statements (Un-audited)
For the Period July 2020 -December 2020

1. Reporting Entity

1.1 About the Company

Beximco Pharmaceuticals Limited (BPL/ the Company) was incorporated as a public limited Company in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). In 2018, BPL acquired 85.22% shares of Nuvista Pharma Limited – a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs and took over control of its management. Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the Company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 The Subsidiaries

Nuvista Pharma Limited (NPL)

Nuvista Pharma, formerly Organon (Bangladesh) Ltd., was a subsidiary of Netherlands based Organon International. It was originally incorporated as a private limited company. In 2006 the foreign holding of the company was sold out to Bangladeshi management and was renamed as Nuvista Pharma Limited. The Company through amendments to its memorandum of association in 2011 converted it into a public limited company. In April 2018, Beximco Pharmaceuticals Limited acquired majority shareholdings in Nuvista Pharma Limited (NPL) and through this acquisition BPL has become the immediate and ultimate parent of the company.

Beximco Pharma API Limited

Beximco Pharma API Limited was formed as a private limited company in December 2017 with a paid up capital of Taka 20 million divided into 2 million shares of Taka 10 each, fully held by BPL. The company intends to set up a facility at API Industrial Park to manufacture Active Pharmaceutical Ingredients (APIs) for domestic and international markets. The company is still in the initial phase of establishment.

1.3 Nature of Business

BPL is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable, Large Volume Intravenous Fluids. Besides formulation products BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the company are sold in domestic and international markets.

NPL produces various pharmaceutical products including oral contraceptives, hormone, steroid, anti-histamine, anti-fibrinolytic, anti-infective, cardiac, gastrointestinal, musculoskeletal, respiratory, vitamin & mineral supplement and women's health products which are sold in the local market.

Both BPL and NPL provides contract manufacturing services.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2020 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

3. Significant Accounting Policies

3.1 Basis of Consolidation

The financial statements of the subsidiaries-Nuvista Pharma Limited and Beximco Pharma API Limited, have been consolidated with those of Beximco Pharmaceuticals Limited in accordance with IFRS 10: Consolidated Financial Statements.

The Company acquired 85.22% shares of the issued paid up capital of Nuvista Pharma Limited. This ownership interest is adequate enough to establish control over NPL and thus BPL meets the conditions as stated in IFRS 10: Consolidated Financial Statements to consider NPL as a subsidiary.

Beximco Pharma API Limited (BPAL) was formed with a paid up capital of Tk.20,000,000 divided into 2,000,000 shares of Tk.10 each, all of which excepting 10 shares are held by Beximco Pharmaceuticals Ltd (BPL). Beximco Pharma API Ltd thus meets the conditions stated in IFRS 10: Consolidated Financial Statements to consider it as a subsidiary.

3.2 Inter-Company Transactions

Assets, Liabilities, Equity, Income, Expenses and Cash Flows arising out of transactions between the Company and the subsidiary have been eliminated in full in the Consolidated Financial Statements.

3.3. Non-Controlling Interests (NCIs)

Non-Controlling Interests (NCIs) at the date of acquisition has been measured at fair value of the net assets of the acquired company in proportion to the shares of the entitled holders. Profit or Loss and Other Comprehensive Income subsequent to the acquisition has been allocated to the Owners of the Company and to the NCIs and also disclosed in the financial statements.

3.4. Valuation of Goodwill

Goodwill has been determined in accordance with IFRS 3: Business Combination. This represents the excess of the aggregate of Purchase Consideration and the acquisition-date fair value of NCI's share in the net assets over the acquisition-date fair value of the net assets of the subsidiary.

3.5 Investment in Associates

Investment in Associates has been accounted for using the Equity method as per IAS 28: Investment in Associates and Joint Ventures.

	As at December 31, 2020	Taka '000 As at June 30, 2020
4. Property, Plant & Equipment - Carrying Value		
Land	4,067,830	4,067,830
Building and Other Constructions	8,099,453	7,822,271
Plant and Machinery	16,653,275	15,766,994
Furniture and Fixtures	337,249	330,454
Transport and Vehicle	830,378	827,287
Office Equipment	628,570	616,852
	30,616,755	29,431,688
Less :Accumulated Depreciation	(10,669,166)	(10,220,348)
Net Book Value	19,947,589	19,211,340
Capital Work in Progress	15,393,601	15,789,470
Carrying Value	35,341,190	35,000,810
5. Other Investment		
Bangladesh Export Import Co. Ltd.	9,685	2,182
Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
	11,254	3,751
6. Inventories		
Finished Goods	1,380,041	1,128,728
Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit)	5,318,695	4,746,573
Physician Sample	70,966	69,468
	6,769,702	5,944,769
7. Loans, Advances and Deposits		
Clearing & Forwarding	255,029	281,675
VAT	405,984	441,075
Security Deposit and Earnest Money	167,677	83,542
Lease Deposit	10,822	10,822
Capital Expenditure / Project	110,868	209,723
Expenses	366,960	263,194
Bank Guarantee Margin	33,712	35,585
Advance against Salary	180,648	161,307
Motor Cycle	150,045	154,443
Raw & Packing Material *	924,276	442,658
Overseas Liaison Office	38,575	40,724
Others	240,127	263,565
	2,884,723	2,388,313

* Includes advance paid for import of COVID-19 Vaccine.

	As at December 31, 2020	Taka '000 As at June 30, 2020
8. Cash and Cash Equivalents		
(a) Cash in Hand (Including Imprest Cash)	257,573	170,479
(b) Cash at Bank:		
Current and FC Account	97,631	426,156
FDR Account	39,401	38,382
	394,605	635,017

9. Long Term Borrowings

A. Net of Current Maturity

Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	1,224,856	1,437,979
Lease Liability	183,409	208,860
Dhaka Bank Limited	-	4,751
	1,408,265	1,651,590

B. Current Maturity

Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	934,057	937,110
Lease Liability	104,460	108,115
Term Loan- AB Bank Limited	130,717	377,803
Dhaka Bank Limited	-	31,284
	1,169,234	1,454,312

C.Exchange fluctuation loss of Tk. 3,775,291 has been incurred on conversion of outstanding foreign currency loan to functional currency at the exchange rate prevailing on the date of Statement of Financial Position.

10. Dividend Payable / Unclaimed Dividend

The cash dividend declared for the year 2019-20 were approved by the shareholders in the Annual General Meeting held on December 19, 2020. The Dividend Payable/Unclaimed dividend as on December 31, 2020 consists of Tk. 608,335K payable for the year 2019-20 and the balance Tk. 81,453K for prior years unclaimed to date. The unclaimed dividend included in Creditors and Other Payables in the prior period has been reclassified in this financial statement.

	For the Period July - December 2020	For the Period July - December 2019
11. Cost of Goods Sold		
Work-in-Process (Opening)	294,258	455,531
Materials Consumed	6,038,741	4,847,748
Factory Overhead Consumed	1,858,471	1,750,026
Total Manufacturing Cost	8,191,470	7,053,305
Work-in-Process (Closing)	(207,829)	(337,139)
Cost of Goods Manufactured	7,983,641	6,716,166
Finished Goods (Opening)	1,128,728	1,255,181
Finished Goods available	9,112,369	7,971,347
Cost of Physician Sample transferred to Sample Stock	(163,729)	(116,477)
Finished Goods (Closing)	(1,380,041)	(1,167,215)
	7,568,599	6,687,655

	Taka '000	
	For the Period July - December 2020	For the Period July - December 2019
12. Administrative Expenses		
Salary & Allowances	239,763	219,313
Repairs & Maintenance	27,253	25,521
Travelling & Conveyance	13,032	13,386
Company Secretarial, Regulatory Fee and AGM Expense	12,149	17,675
Depreciation	16,595	17,273
Security Expenses	6,226	4,622
Other Expenses	88,614	90,914
	403,632	388,704
13. Selling, Marketing and Distribution Expenses		
Salary & Allowances	1,144,980	1,035,326
Travelling & Conveyance	301,851	300,270
Market Research & New Products	24,639	34,407
Sample Expenses	213,749	195,762
Literature and News Letter	121,743	107,617
Events, Programs & Campaigns	96,329	92,004
Brand Development	61,188	43,993
Sales Promotion Expenses	63,250	65,159
Distribution Commission	215,252	178,117
Delivery Expense	200,938	178,855
Depreciation and Amortization	78,055	71,901
Export Insurance, Freight and C & F Expenses	71,291	139,728
Security Expenses	9,124	8,922
Allowance for Bad Debts	1,525	1,783
Other Expenses	357,176	207,429
	2,961,090	2,661,273
14. Other Income		
Interest Income	1,318	15,546
Cash Incentive on Export	145,235	49,822
Royalty	21,248	77,825
Exchange Rate Fluctuation Gain/(loss)	452	(6,994)
Profit/(Loss) on Sale / Retirement of Fixed Assets	-	(6)
Sale of Product Dossier	989	-
Miscellaneous Income	671	572
	169,913	136,765

	For the Period July - December 2020	Taka '000 For the Period July - December 2019
15. Deferred Tax Expense /(Income)		
Deferred Tax is arrived at as follows :		
Property, Plant & Equipment (Difference in book value & Tax base)	9,830,702	9,540,139
Deferred Liability (Gratuity)	(1,248,669)	(1,109,802)
Allowance for Bad Debts	(8,079)	-
Temporary Difference	8,573,954	8,430,337
Tax Rate		
Deferred Tax Liability at end of the period	2,194,846	2,140,385
Deferred Tax Liability at beginning of the period	2,167,684	2,118,775
Change in Deferred Tax Liability	27,162	21,610
Deferred Tax on Revaluation Surplus	898	(17,235)
Deferred Tax Expense/(Income)	28,060	4,375

16. Earnings Per Share (EPS)/Restated EPS

Consolidated EPS of comparative July-December 2019 period (Prior Period) has been restated for the issuance of 10% stock dividend for the year 2019-20. Additionally, Other Income reported for the Prior Period was rectified in line with the year-end audited financial statements for an amount of Tk.20,027K being an inter-company transaction. The Statements of Cash flow and Retained Earnings has been adjusted accordingly. Comparative Prior Period EPS without such correction would have been Taka 3.87 instead of Taka 3.83 as reported.

17. Reconciliation of Net Profit with Cash Flows from Operating Activities

Profit After Tax	2,226,299	1,715,346
Adjustment to reconcile net profit to net cash Generated from Operating Activities :		
Non-Cash Expenses :	762,690	610,589
Depreciation	484,645	502,437
Amortization	45,553	37,198
Gratuity & WPPF	204,432	66,579
Deferred tax	28,060	4,375
Non-operating items:	3,770	9,746
Exchange rate fluctuation loss on Foreign Currency Bank Loan	3,775	10,346
(Profit)/Loss on sale of Fixed Assets	(5)	6
Effect of exchange rate changes on Cash and Cash Equivalents	-	(606)
Changes in Working Capital	(803,095)	1,371,825
Inventories	(824,933)	452,629
Spares & Supplies	(82,852)	79,973
Accounts Receivable	396,248	254,099
Loans, Advances & Deposits	(493,724)	248,576
Advance Income Tax	-	35,681
Creditors and Other Payables	(175,407)	(33,013)
Accrued Expenses	107,689	53,934
Income Tax Payable	269,884	279,946
Net Cash Generated from Operating Activities	2,189,664	3,707,506

18. Related Party Transaction

Name of Related Parties	Nature of Transactions	Value of Transaction	Balance at period end
I & I Services Ltd.*	Local Delivery Distribution Commission	13,942,436 215,252	1,781,441

* I & I Services Ltd. provides local distribution services to BPL.

19. Significant Deviations

Operating cash flow per share declined as compared to July-December 2019 because the Company had to maintain higher inventory to protect against any supply chain disruptions due to the COVID-19 and to support the organic business growth. Additionally, the Company paid a significant amount as advance to Serum Institute for the import of COVID-19 vaccine.

20. Events after the reporting period:

20.1 As per agreement with the Serum Institute of India Pvt. Ltd ("SII") and the Government of Bangladesh ("GOB"), the Company has imported 5 (five) million doses of the Oxford University/AstraZeneca SARS-CoV-2 vaccine, AZD1222 for onward delivery to GOB.

20.2 The Company has entered into a binding commitment with Sanofi group for the acquisition of 54.6% stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh"). The acquisition is subject to approval by the Foreign Exchange Investment Department of Bangladesh Bank and completing the Share Purchase Agreement.

Osman Kaiser Chowdhury
Director

A B Siddiquir Rahman
Director

Nazmul Hassan
Managing Director

Mohammad Ali Nawaz
Chief Financial Officer

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Financial Statements (Un-audited)
Beximco Pharmaceuticals Ltd.

Beximco Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at December 31, 2020

			Taka '000
	Notes	December 31, 2020	June 30, 2020
ASSETS			
Non-Current Assets			
		36,590,172	36,240,980
Property, Plant and Equipment- Carrying Value	3	33,610,506	33,244,656
Right-of-use Assets		234,574	237,100
Intangible Assets		559,326	580,961
Investment in Subsidiaries		2,145,186	2,145,186
Investment In Associates		29,326	29,326
Other Investments	4	11,254	3,751
Current Assets			
		13,143,229	12,438,793
Inventories	5	6,314,221	5,528,438
Spares & Supplies		815,430	735,704
Accounts Receivable		2,832,860	3,213,666
Loans, Advances and Deposits	6	2,818,460	2,345,040
Cash and Cash Equivalents	7	362,258	615,945
TOTAL ASSETS		49,733,401	48,679,773
EQUITY AND LIABILITIES			
Shareholders' Equity			
		33,898,729	32,356,359
Issued Share Capital		4,461,120	4,055,564
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,123,076	1,125,768
Unrealized Gain/(Loss)		8,429	926
Retained Earnings		21,052,041	19,920,038
Non-Current Liabilities			
		5,654,104	5,692,973
Long Term Borrowings-Net of Current Maturity	8 A	1,408,265	1,641,924
Liability for Gratuity and WPPF & Welfare Funds		2,178,049	2,015,304
Deferred Tax Liability		2,067,790	2,035,745
Current Liabilities and Provisions			
		10,180,568	10,630,441
Short Term Borrowings		6,035,093	6,987,531
Long Term Borrowings-Current Maturity	8 B	1,169,234	1,421,497
Creditors and Other Payables		1,052,554	1,267,070
Accrued Expenses		729,813	609,401
Dividend Payable / Unclaimed Dividend	9	689,448	81,793
Income Tax Payable		504,426	263,149
TOTAL EQUITY AND LIABILITIES		49,733,401	48,679,773




Osman Kaiser Chowdhury
Director



A B Siddiqui Rahman
Director



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July-December 2020

	Notes	July - December 2020	July - December 2019	October - December 2020	October - December 2019
				Taka '000	
Net Sales Revenue		13,196,162	11,505,635	6,853,828	5,690,793
Cost of Goods Sold	10	(6,995,893)	(6,211,152)	(3,636,178)	(3,080,909)
Gross Profit		6,200,269	5,294,483	3,217,650	2,609,884
Operating Expenses		(3,018,689)	(2,745,976)	(1,568,975)	(1,379,867)
Administrative Expenses	11	(352,020)	(348,593)	(179,788)	(175,465)
Selling, Marketing and Distribution Expenses	12	(2,666,669)	(2,397,383)	(1,389,187)	(1,204,402)
Profit from Operations		3,181,580	2,548,507	1,648,675	1,230,017
Other Income	13	282,560	221,218	151,738	129,663
Finance Cost		(492,702)	(498,789)	(265,976)	(213,014)
Profit Before Contribution to WPPF & Welfare Funds		2,971,438	2,270,936	1,534,437	1,146,666
Contribution to WPPF & Welfare Funds		(141,497)	(108,140)	(73,068)	(54,603)
Profit Before Tax		2,829,941	2,162,796	1,461,369	1,092,063
Income Tax Expenses		(687,637)	(487,494)	(347,295)	(252,028)
Current Tax		(654,694)	(481,721)	(330,667)	(239,642)
Deferred Tax	14	(32,943)	(5,773)	(16,628)	(12,386)
Profit after Tax		2,142,304	1,675,302	1,114,074	840,035
Other Comprehensive Income - Unrealized Gain/(Loss)		7,503	(1,444)	5,606	(773)
Total Comprehensive Income		2,149,807	1,673,858	1,119,680	839,262

Earnings Per Share (EPS)/Restated EPS	4.80	3.76	2.50	1.88
Number of Shares Used to Compute EPS	446,112,089	446,112,089	446,112,089	446,112,089

 Osman Kaiser Chowdhury Director	 A B Siddiquir Rahman Director	 Nazmul Hassan Managing Director	 Mohammad Ali Nawaz Chief Financial Officer	 Mohammad Asad Ullah, FCS Executive Director & Company Secretary
--	--	--	--	--

Beximco Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the Period July-December 2020

As at December 31, 2020

Taka' 000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Total	
Balance as on July 01, 2020	4,055,564	5,269,475	1,689,637	294,951	1,125,768	926	19,920,038	32,356,359	
Total Comprehensive Income									
Profit for the Year	-	-	-	-	-	-	2,142,304	2,142,304	
Other Comprehensive Income/(Loss)	-	-	-	-	-	7,503	-	7,503	
Transactions with the Shareholders:									
Cash Dividend	-	-	-	-	-	-	(608,335)	(608,335)	
Stock Dividend	405,556	-	-	-	-	-	(405,556)	-	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(3,590)	-	3,590	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	898	-	-	898	
Balance as on December 31, 2020	4,461,120	5,269,475	1,689,637	294,951	1,123,076	8,429	21,052,041	33,898,729	
Number of Shares									446,112,089
Net Asset Value (NAV) Per Share								Tk.	75.99

As at December 31, 2019

Taka' 000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Total	
Balance as on July 01, 2019	4,055,564	5,269,475	1,689,637	294,951	1,131,853	2,504	17,156,859	29,600,843	
Total Comprehensive Income :									
Profit for the Period	-	-	-	-	-	-	1,675,302	1,675,302	
Other Comprehensive Income / (Loss)	-	-	-	-	-	(1,444)	-	(1,444)	
Transaction with the Shareholders :									
Cash Dividend	-	-	-	-	-	-	(608,335)	(608,335)	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(4,057)	-	4,057	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	-	-	-	-	
Balance as on December 31, 2019	4,055,564	5,269,475	1,689,637	294,951	1,127,796	1,060	18,227,883	30,666,366	
Number of Shares									405,556,445
Net Asset Value (NAV) Per Share								Tk.	75.62

Osman Kaiser Chowdhury
Director

A B Siddiqui Rahman
Director

Nazmul Hassan
Managing Director

Mohammad Ali Nawaz
Chief Financial Officer

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the Period July-December 2020

	Notes	July - December 2020	Taka '000 July - December 2019
Cash Flows from Operating Activities :			
Receipts from Customers and Others		13,826,936	11,988,110
Payments to Suppliers and Employees		(10,939,309)	(7,806,819)
Cash Generated from Operations		2,887,627	4,181,291
Interest Paid		(492,702)	(498,789)
Interest Received		1,318	15,547
Income Tax Paid		(413,417)	(204,007)
Net Cash Generated from Operating Activities	15	1,982,826	3,494,042
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(841,092)	(1,296,454)
Intangible Assets		(8,819)	(13,065)
Disposal of Property, Plant and Equipment		21,166	3,342
Dividend Received		35,047	20,027
Decrease in Short Term Investment		-	127,785
Net Cash Used in Investing Activities		(793,698)	(1,158,365)
Cash Flows from Financing Activities :			
Net Increase /(Decrease) in Long Term Borrowings		(489,697)	(682,043)
Net Increase/(Decrease) in Short Term Borrowings		(952,438)	(1,767,339)
Dividend Paid		(680)	(423)
Net Cash (Used in) / from Financing Activities		(1,442,815)	(2,449,805)
Increase/(Decrease) in Cash and Cash Equivalents		(253,687)	(114,128)
Cash and Cash Equivalents at Beginning of Period		615,945	582,306
Effect of exchange rate changes on Cash and Cash Equivalents*		-	606
Cash and Cash Equivalents at End of Period	7	362,258	468,784
Net Operating Cash Flow Per Share		4.44	8.62

*The Company used Janata Bank's end of periods US Dollar-BDT exchange rates as on 31 December 2020 which remained unchanged with the exchange rates as at 30 June 2020. As such there was no effect of exchange rates in the cash flow.

 Osman Kaiser Chowdhury Director	 A B Siddiqui Rahman Director	 Nazmul Hassan Managing Director	 Mohammad Ali Nawaz Chief Financial Officer	 Mohammad Asad Ullah, FCS Executive Director & Company Secretary
--	---	--	--	--

Beximco Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-audited)
For the Period July-December 2020

1. Reporting Entity

1.1 About the company

Beximco Pharmaceuticals Limited (BPL/ the Company) was incorporated as a public limited Company in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). In 2018, BPL acquired 85.22% shares of Nuvista Pharma Limited – a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs and took over control of its management. Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the Company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 Nature of Business

The company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable, Large Volume Intravenous Fluids. BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the company are sold in domestic and international markets.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2020 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

Taka '000

	As at December 31, 2020	As at June 30, 2020
3. Property, Plant & Equipment - Carrying Value		
Land	3,343,741	3,343,741
Building and Other Constructions	7,774,978	7,499,762
Plant and Machinery	15,371,722	14,495,139
Furniture and Fixtures	285,772	281,072
Transport and Vehicle	686,005	686,005
Office Equipment	596,690	585,815
	28,058,908	26,891,534
Less :Accumulated Depreciation	(9,812,741)	(9,416,167)
Net Book Value	18,246,167	17,475,367
Capital Work in Progress	15,364,339	15,769,289
Carrying Value	33,610,506	33,244,656
4. Other Investment		
Bangladesh Export Import Co. Ltd.	9,685	2,182
Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
	11,254	3,751
5. Inventories		
Finished Goods	1,246,265	972,564
Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit)	4,996,990	4,486,406
Physician Sample	70,966	69,468
	6,314,221	5,528,438
6. Loans, Advances and Deposits		
Clearing & Forwarding	255,029	281,675
VAT	383,396	419,480
Security Deposit and Earnest Money	136,721	76,961
Lease Deposit	10,822	10,822
Capital Expenditure / Project Expenses	110,868	209,723
	366,960	263,194
Bank Guarantee Margin	33,712	35,585
Advance against Salary	175,746	157,726
Motor Cycle	150,045	154,443
Raw & Packing Material *	924,276	442,659
Overseas Liaison Office	38,575	40,725
Others	232,310	252,047
	2,818,460	2,345,040

* Includes advance paid for import of COVID-19 Vaccine.

	As at December 31, 2020	As at June 30, 2020
Taka '000		
7. Cash and Cash Equivalents		
(a) Cash in Hand (Including Imprest Cash)	257,136	170,284
(b) Cash at Bank:		
Current and FC Account	65,721	407,280
FDR Account	39,401	38,381
	<u>362,258</u>	<u>615,945</u>
8. Long Term Borrowings		
A. Net of Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	1,224,856	1,437,979
Leases Liability	183,409	203,945
	<u>1,408,265</u>	<u>1,641,924</u>
B. Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	934,057	937,110
Leases Liability	104,460	106,584
Term Loan - AB Bank Limited	130,717	377,803
	<u>1,169,234</u>	<u>1,421,497</u>
C. Exchange fluctuation loss of Tk. 3,775,291 has been incurred on conversion of outstanding foreign currency loan to functional currency at the exchange rate prevailing on the date of Statement of Financial Position.		

9. Dividend Payable / Unclaimed Dividend

The cash dividend declared for the year 2019-20 were approved by the shareholders in the Annual General Meeting held on December 19, 2020. The Dividend Payable/Unclaimed dividend as on December 31, 2020 consists of Tk. 608,335K payable for the year 2019-20 and the balance Tk. 81,113K for prior years unclaimed to date. The unclaimed dividend included in Creditors and Other Payables in the prior period has been reclassified in this financial statement.

	For the Period July - December 2020	For the Period July - December 2019
10. Cost of Goods Sold		
Work-in-Process (Opening)	249,839	420,136
Materials Consumed	5,728,993	4,569,340
Factory Overhead Consumed	1,607,922	1,507,827
Total Manufacturing Cost	7,586,754	6,497,303
Work-in-Process (Closing)	(158,411)	(255,391)
Cost of Goods Manufactured	7,428,343	6,241,912
Finished Goods (Opening)	972,564	1,155,804
Finished Goods available	8,400,907	7,397,716
Cost of Physician Sample transferred to Sample Stock	(158,749)	(112,618)
Finished Goods (Closing)	(1,246,265)	(1,073,946)
	<u>6,995,893</u>	<u>6,211,152</u>

	For the Period July - December 2020	Taka '000 For the Period July - December 2019
11. Administrative Expenses		
Salary & Allowances	207,924	193,322
Repairs & Maintenance	24,762	23,261
Travelling & Conveyance	12,385	13,067
Company Secretarial, Regulatory Fee and AGM Expense	11,814	17,045
Depreciation	15,135	15,703
Security Expenses	6,226	4,622
Other Expenses	73,774	81,573
	352,020	348,593
12. Selling, Marketing and Distribution Expenses		
Salary & Allowances	990,840	902,784
Travelling & Conveyance	261,469	264,019
Market Research & New Products	24,639	34,407
Sample Expenses	206,576	190,351
Literature and News Letter	108,747	96,512
Events, Programs & Campaign	91,346	88,450
Brand Development	57,532	40,837
Sales Promotion Expenses	55,339	58,216
Distribution Commission	215,252	178,117
Delivery Expense	200,938	178,855
Depreciation and Amortization	56,399	49,017
Export Insurance, Freight and C & F Expenses	71,291	139,728
Security Expenses	9,124	8,922
Allowance for Bad Debts	1,525	1,783
Other Expenses	315,652	165,385
	2,666,669	2,397,383
13. Other Income		
Interest Income	1,318	15,546
Distribution Commission	65,919	53,928
Cash Incentive on Export	145,235	49,822
Dividend Income	35,047	20,027
Royalty	33,600	88,889
Exchange Rate Fluctuation Gain/(loss)	452	(6,994)
Sale of Product Dossier	989	-
	282,560	221,218
14. Deferred Tax		
Deferred Tax is arrived at as follows :		
Property, Plant & Equipment (Difference in book value & Tax base)	9,385,701	9,097,753
Deferred Liability (Gratuity)	(1,107,872)	(995,435)
Allowance for Bad Debts	(6,669)	-
Temporary Difference	8,271,160	8,102,318
Tax Rate	25%	25%
Deferred Tax Liability at end of the period	2,067,790	2,025,579
Deferred Tax Liability at beginning of the period	2,035,745	2,002,571
Change in Deferred Tax Liability	32,045	23,008
Deferred Tax on Revaluation Surplus	898	(17,235)
Deferred Tax	32,943	5,773

Taka '000

For the Period
July - December 2020For the Period
July - December 2019**15. Reconciliation of Net Profit with Cash Flows from Operating Activities**

Profit after Tax	2,142,304	1,675,302
Adjustment to reconcile net profit to net cash Generated from Operating Activities :		
Non-cash Expenses :	658,565	514,074
Depreciation	432,424	448,652
Amortization	30,453	22,098
Gratuity & WPPF	162,745	37,551
Deferred Tax	32,943	5,773
Non-operating items:	(31,272)	(10,287)
Exchange rate fluctuation loss on Foreign Currency Bank Loan	3,775	10,346
Dividend Income	(35,047)	(20,027)
Effect of exchange rate changes on Cash and Cash Equivalents	-	(606)
Changes in Working Capital	(786,771)	1,314,952
Inventories	(785,783)	443,044
Spares & Supplies	(79,726)	78,793
Accounts Receivable	380,806	287,091
Loans, Advances & Deposits	(473,420)	252,786
Creditors and Other Payables	(190,337)	(10,626)
Accrued Expenses	120,412	(13,851)
Income Tax Payable	241,277	277,715
Net Cash Generated from Operating Activities	1,982,826	3,494,042

16. Related Party Transactions

Name of Related Parties	Nature of Transactions	Value of Transaction	Balance at period end
a. I & I Services Ltd.*	Local Delivery Distribution Commission	13,942,436 215,252	1,781,441
b. Nuvista Pharma Ltd	Toll Manufacturing Cost of services Dividend Distribution commission	13,017 40,423 35,047 65,919	1,810 7,256 - 12,761
c. Beximco Pharma API Limited	Short Term Advance	120	664

* I & I Services Ltd. provides local distribution services to BPL.

17. Significant Deviations


Operating cash flow per share declined as compared to July-December 2019 because the Company had to maintain higher inventory to protect against any supply chain disruptions due to the COVID-19 and to support the organic business growth. Additionally, the Company paid a significant amount as advance to Serum Institute for the import of COVID-19 vaccine.


18. Events after the reporting period:


18.1. As per agreement with the Serum Institute of India Pvt. Ltd ("SII") and the Government of Bangladesh ("GOB"), the Company has imported 5 (five) million doses of the Oxford University/AstraZeneca SARS-CoV-2 vaccine, AZD1222 for onward delivery to GOB.

18.2 The Company has entered into a binding commitment with Sanofi group for the acquisition of 54.6% stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh"). The acquisition is subject to approval by the Foreign Exchange Investment Department of Bangladesh Bank and completing the Share Purchase Agreement.


Osman Kaiser Chowdhury
Director


A B Siddiquir Rahman
Director


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary